C4 Therapeutics (NASDAQ:CCCC – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $4.43 million for the quarter.
C4 Therapeutics Price Performance
Shares of CCCC stock opened at $2.79 on Wednesday. The company’s fifty day moving average price is $3.59 and its two-hundred day moving average price is $4.86. The firm has a market capitalization of $196.94 million, a P/E ratio of -1.64 and a beta of 2.95. C4 Therapeutics has a 12 month low of $2.69 and a 12 month high of $11.88.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. Stephens began coverage on C4 Therapeutics in a research report on Monday, November 18th. They issued an “equal weight” rating and a $4.00 target price on the stock. Wells Fargo & Company upgraded shares of C4 Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $8.00 to $12.00 in a research note on Thursday, December 19th. Finally, UBS Group raised shares of C4 Therapeutics to a “hold” rating in a research report on Friday, February 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, C4 Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.60.
About C4 Therapeutics
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Featured Articles
- Five stocks we like better than C4 Therapeutics
- What to Know About Investing in Penny Stocks
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Should You Invest in Penny Stocks?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What Is WallStreetBets and What Stocks Are They Targeting?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
